https://mtimes.net Real-time English, Japanese, and Chinese financial news, South Korean stock market analysis, corporate governance, and global tech supply chain intelligence. en-us Thu, 05 Nov 2026 12:45:11 GMT Copyright 2026 MTIMES Global. All rights reserved. https://mtimes.net/article/1451 https://mtimes.net/article/1451 Thu, 05 Nov 2026 04:02:48 GMT Verismo Therapeutics, a US subsidiary of HLB Innovation, has reported promising Phase I clinical results for its next-generation CAR-T therapy, "SynKIR-310," demonstrating a 60% complete remission rate in relapsed or refractory blood cancer patients without major immunotoxicity. Headline editorial@mtimes.net (Kim Jeong-eun Reporter) https://mtimes.net/article/1449 https://mtimes.net/article/1449 Thu, 05 Nov 2026 00:49:27 GMT The Democratic sweep of the House, Senate, and governorships in the US midterm elections is reshaping global equity sector strategies. While policy uncertainties weigh on artificial intelligence (AI) infrastructure, green energy, batteries, and biotech are seeing shifting investor dynamics amid expectations of regulatory pushback and falling bond yields. Markets editorial@mtimes.net (Park Hae-soo Reporter) https://mtimes.net/article/1442 https://mtimes.net/article/1442 Wed, 04 Nov 2026 02:26:51 GMT As the European Union expands its defense financing program with stringent local content requirements—capping non-European components at 35%—South Korean defense contractors face a structural shift, forcing a move beyond traditional finished-product exports toward localized manufacturing and supply chains. Industry editorial@mtimes.net (Kim Jeong-eun Reporter) https://mtimes.net/article/1452 https://mtimes.net/article/1452 Thu, 05 Nov 2026 05:58:34 GMT Despite projected production increases and sluggish consumer demand, robust appetite for AI server memory is Industry editorial@mtimes.net (Song Jung-hee Reporter) https://mtimes.net/article/1445 https://mtimes.net/article/1445 Wed, 04 Nov 2026 07:38:35 GMT Korean equities claw back sharp intraday losses to close higher, though persistent foreign capital outflows leave analysts divided on the trajectory of a recovery. Markets editorial@mtimes.net (Kim Jeong-eun Reporter) https://mtimes.net/article/1430 https://mtimes.net/article/1430 Mon, 02 Nov 2026 22:37:22 GMT SpaceX and Amazon are pouring billions into spectrum and telecom acquisitions to dominate the direct-to-device satellite market, shifting the space race from constellation deployment to terrestrial subscriber acquisition. Meanwhile, South Korea is weighing a multi-billion-dollar independent low-Earth orbit network. Industry editorial@mtimes.net (Kim Jeong-eun Reporter) https://mtimes.net/article/1436 https://mtimes.net/article/1436 Tue, 03 Nov 2026 06:27:46 GMT Expanding North American LNG and energy infrastructure investments are creating new order opportunities for South Korean steelmakers, with firms securing tangible contracts in Canada and positioning themselves for potential projects in Alaska. However, a sharp rise in South Korean steel imports has drawn scrutiny from the U.S. steel industry, raising concerns over growing trade barriers. Industry editorial@mtimes.net (Kim Jeong-eun Reporter) https://mtimes.net/article/1426 https://mtimes.net/article/1426 Mon, 02 Nov 2026 08:35:42 GMT As the race to build artificial intelligence infrastructure intensifies, third-quarter capital expenditures at Meta and Alphabet have outstripped their operating cash flows, while Microsoft maintains a positive free cash flow, highlighting a growing divergence in corporate financing capabilities. Markets editorial@mtimes.net (Song Jung-hee Reporter) https://mtimes.net/article/1410 https://mtimes.net/article/1410 Sun, 01 Nov 2026 03:17:17 GMT As the KOSDAQ index flirts with the 720 threshold, market participants are increasingly demanding regulatory overhauls, including a ban on short-selling, the abolition of investor-caution designations, and the relaxation of earnings-loss rules tailored to R&D-heavy growth companies. Markets editorial@mtimes.net (Park Hae-soo Reporter) https://mtimes.net/article/1412 https://mtimes.net/article/1412 Sun, 01 Nov 2026 23:00:41 GMT As Wall Street faces recent volatility—highlighted by a sharp 7.2% drop in the Philadelphia Semiconductor Index—market attention turns to the historical pattern surrounding U.S. midterm elections. While data shows a seemingly flawless 100% win rate for U.S. equities from October of a midterm year through June of the following year, a closer look reveals statistical nuances worth noting. Finance & Securities editorial@mtimes.net (Lee Kyung-hee Reporter) https://mtimes.net/article/1414 https://mtimes.net/article/1414 Sun, 01 Nov 2026 23:42:41 GMT Exports of non-semiconductor items jumped 34% year-on-year in October, powered by a record-breaking performance in electrical equipment and robust gains across cosmetics and bio-health. While stellar chip demand led the headline numbers, 18 of South Korea's top 20 export categories registered growth. Industry editorial@mtimes.net (Song Jung-hee Reporter) https://mtimes.net/article/1241 https://mtimes.net/article/1241 Thu, 15 Oct 2026 00:54:49 GMT The U.S. September Consumer Price Index (CPI) report has rattled financial markets, as "sticky" core inflation pressures raise the possibility of an earlier-than-expected interest rate hike by the Federal Reserve. Finance & Securities editorial@mtimes.net (Park Hae-soo Reporter) https://mtimes.net/article/1214 https://mtimes.net/article/1214 Mon, 12 Oct 2026 23:51:43 GMT South Korean biotech firm Mezzion Pharma is expanding its pivotal Phase 3 trial for Udenafil to Europe as it moves toward a potential 2027 FDA filing, with peak annual U.S. sales estimated at $3 billion. Corporate editorial@mtimes.net (Song Jung-hee Reporter) https://mtimes.net/article/1162 https://mtimes.net/article/1162 Tue, 06 Oct 2026 22:55:31 GMT HLB Therapeutics CEO An Ki-hong emphasized that the superior convenience and safety profile of RGN-259 will drive its adoption as a primary treatment for neurotrophic keratitis (NK), with top-line results from the SEER-2 global Phase 3 clinical trial expected by mid-November. Corporate editorial@mtimes.net (Kim Jeong-eun Reporter) https://mtimes.net/article/1146 https://mtimes.net/article/1146 Mon, 05 Oct 2026 21:42:37 GMT HLB Therapeutics is preparing for a make-or-break moment in November, as it awaits the top-line results of its U.S. Phase 3 "SEER-2" trial for the neurotrophic keratitis (NK) treatment candidate RGN-259. The company aims to challenge the U.S. market dominance of Dompé’s "Oxervate," leveraging the logistical advantages of a shelf-stable, short-term treatment regimen. Corporate editorial@mtimes.net (Kim Jeong-eun Reporter) https://mtimes.net/article/1141 https://mtimes.net/article/1141 Sat, 03 Oct 2026 02:18:40 GMT AriBio’s U.S. division head, Fred Kim, outlined the company’s ambition to position its oral Alzheimer’s candidate, AR1001, as a first-line treatment, with global Phase 3 trial results set for release in November 2026. Corporate editorial@mtimes.net (Song Jung-hee Reporter) https://mtimes.net/article/1135 https://mtimes.net/article/1135 Fri, 02 Oct 2026 08:03:16 GMT ArisBio is gearing up for the pivotal November release of its Phase 3 global clinical trial results for its oral Alzheimer's treatment candidate, AR1001, setting its sights on U.S. FDA approval by 2028 and a 1 trillion won revenue milestone by 2030. Corporate editorial@mtimes.net (Song Jung-hee Reporter) https://mtimes.net/article/1128 https://mtimes.net/article/1128 Fri, 02 Oct 2026 00:05:00 GMT While the KOSPI finished September in positive territory, the broader market suffered a severe breadth contraction as heavyweights Samsung Electronics and SK hynix propped up the index while nearly 70% of listed issues declined. Markets editorial@mtimes.net (Kim Jeong-eun Reporter) https://mtimes.net/article/1117 https://mtimes.net/article/1117 Wed, 30 Sep 2026 23:01:34 GMT Behind Micron’s robust quarterly earnings lies an even stronger industry signal, as hyperscalers and AI data centers rush to lock in memory supply agreements stretching all the way to 2031. Corporate editorial@mtimes.net (Kim Jeong-eun Reporter) https://mtimes.net/article/1113 https://mtimes.net/article/1113 Wed, 30 Sep 2026 09:33:40 GMT Global technology giants are moving beyond conversational chatbots to always-on autonomous AI agents capable of executing tasks, scheduling, and data analysis in the background without user intervention. Industry editorial@mtimes.net (Kim Jeong-eun Reporter) https://mtimes.net/article/1348 https://mtimes.net/article/1348 Mon, 26 Oct 2026 21:48:11 GMT HanAll Biopharma’s autoimmune disease treatment batoclimab has received marketing approval in China following successful Phase 3 clinical trials, paving the way for milestone payments and sales royalties. Meanwhile, its next-generation candidate, imireprovat (IMVT-1402), is undergoing global Phase 3 trials for generalized myasthenia gravis, with early therapeutic responses also observed in rheumatoid arthritis. Corporate editorial@mtimes.net (Song Jung-hee Reporter) https://mtimes.net/article/1454 https://mtimes.net/article/1454 Thu, 05 Nov 2026 07:35:22 GMT Korea Aerospace Industries (KAI) has secured a confidential overseas export contract valued at approximately 1.4 trillion won, fueling market speculation that the deal involves either FA-50 light attack aircraft or Surion utility helicopters as the company expands its global footprint. Corporate editorial@mtimes.net (Kim Jeong-eun Reporter) https://mtimes.net/article/1456 https://mtimes.net/article/1456 Thu, 05 Nov 2026 08:09:18 GMT Samsung Electronics retains top spot with 38% market share, while SK hynix surges to 29% on the back of strong HBM3E demand. As the industry faces a price-driven supercycle, the focus shifts to the next-generation HBM4 market. Corporate editorial@mtimes.net (Lee Kyung-hee Reporter) https://mtimes.net/article/1431 https://mtimes.net/article/1431 Mon, 02 Nov 2026 23:09:52 GMT Hoban Group's recent stake purchases in Hanjin Kal could elevate it to the top shareholder, surpassing Chairman Cho Won-tae. However, securing actual management control remains a formidable challenge amid solid friendly stakes, an incumbent board without Hoban representation, and the uncertain future of the Korea Development Bank’s 10.58% holding. Corporate editorial@mtimes.net (Lee Kyung-hee Reporter) https://mtimes.net/article/1441 https://mtimes.net/article/1441 Wed, 04 Nov 2026 01:07:04 GMT U.S. chipmaker AMD reported record third-quarter revenue, fueled by surging demand for artificial intelligence infrastructure. Driven by a 97% jump in its data center division, the company issued a strong fourth-quarter revenue forecast of $170 billion, though CEO Lisa Su noted that robust AI demand continues to outpace available supply. Corporate editorial@mtimes.net (Song Jung-hee Reporter) https://mtimes.net/article/1420 https://mtimes.net/article/1420 Mon, 02 Nov 2026 04:47:16 GMT Hanwha has secured its first U.S. Navy contract to build medium landing ships, marking a major milestone as a South Korean shipbuilder enters the domestic-only U.S. naval market through strategic local acquisitions and advanced manufacturing technology. Corporate editorial@mtimes.net (Kim Jeong-eun Reporter) https://mtimes.net/article/1408 https://mtimes.net/article/1408 Sun, 01 Nov 2026 00:44:02 GMT Anthropic is aggressively expanding into the life sciences sector, moving beyond supplying research-grade AI to pharmaceutical firms to directly participating in drug discovery with its own research organization and laboratories. The company plans to deploy its Claude model across target design, experimental data analysis, and clinical trial planning. Corporate editorial@mtimes.net (Song Jung-hee Reporter) https://mtimes.net/article/1439 https://mtimes.net/article/1439 Tue, 03 Nov 2026 23:21:04 GMT HLB's liver cancer treatment has entered the formal review stage at the US Food and Drug Administration (FDA), with a target decision date set for April 9, 2027. Following its recent success in cholangiocarcinoma, the company is eyeing its second major commercialization milestone in the US market. Corporate editorial@mtimes.net (Kim Jeong-eun Reporter) https://mtimes.net/article/1450 https://mtimes.net/article/1450 Thu, 05 Nov 2026 02:53:26 GMT Participating in Europe's largest pharmaceutical and bio partnering event to be held in Cologne, Germany from the 9th to the 11th. First disclosure regardi... Corporate editorial@mtimes.net (Song Jung-hee Reporter) https://mtimes.net/article/1425 https://mtimes.net/article/1425 Mon, 02 Nov 2026 08:09:44 GMT POSCO Holdings has unveiled detailed plans for the 2.5 trillion won ($1.8 billion) secured through the monetization of affiliate stakes. The company will channel approximately 1.1 trillion won into acquiring a stake in an Australian lithium mine and allocate 2500 billion won to share buybacks and cancellations within the year, fast-tracking shareholder returns ahead of additional asset sales. Corporate editorial@mtimes.net (Lee Kyung-hee Reporter)